List of Safyral drug patents

Safyral is owned by Bayer Hlthcare.

Safyral contains Drospirenone; Ethinyl Estradiol; Levomefolate Calcium.

Safyral has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Safyral are:

  • US7163931

Safyral was authorised for market use on 16 December, 2010.

Safyral is available in tablet;oral dosage forms.

Safyral can be used as prevention of pregnancy.

The generics of Safyral are possible to be released after 08 February, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7163931 BAYER HLTHCARE Compositions of estrogen-cyclodextrin complexes
Mar, 2022

(1 year, 24 days ago)

US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Feb, 2030

(6 years from now)

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Market Authorisation Date: 16 December, 2010

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

How can I launch a generic of SAFYRAL before it's patent expiration?
More Information on Dosage

SAFYRAL family patents

8

United States

3

Australia

3

Korea, Republic of

3

European Union

2

Israel

2

Denmark

2

Slovenia

2

Hungary

2

Croatia

2

Spain

2

Czech Republic

2

China

2

Japan

EA

2

EA

2

Canada

2

ME

1

South Africa

IB

1

IB

1

Slovakia

1

Austria

1

Mexico

1

Hong Kong

1

Lithuania

1

Uruguay

1

Norway

1

Germany

1

Argentina

1

Brazil

1

Portugal

1

Cyprus

YU

1

Yugoslavia

1

Peru

1

Poland

1

RS

1

Taiwan, Province of China

1

Ukraine

1

Bulgaria

1

Estonia

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in